Overview
SomaLogic offers the SomaScan Assay, a high-plex proteomics platform measuring over 7,000 proteins simultaneously from small plasma or serum samples with high sensitivity, specificity, and reproducibility. It supports biomarker discovery, drug development, diagnostics, and clinical testing for cardiovascular risk, cancer, and other diseases. Now part of Illumina, it enables multiomics insights for pharmaceutical R&D and health management.
Frequently asked questions
- What proteomics capabilities does SomaLogic provide?
- The SomaScan Assay measures over 7,000 proteins from 55-µl plasma/serum samples, offering high-plex, high-throughput analysis for biomarker discovery, drug development, and clinical testing across species and sample types.
- What are SomaLogic's clinical offerings?
- SomaSignal Tests use protein patterns from blood to predict health states and disease risks, such as 4-year cardiovascular event likelihood, validated in diverse global populations.
- How does SomaLogic support pharma R&D?
- Curated SomaScan Panels target proteins for drug discovery/development, cancer proteomics covering half the proteome, and integration with Illumina for multiomics biomarker and disease profiling.